T Shukuya

Summary

Affiliation: Juntendo University School of Medicine
Country: Japan

Publications

  1. ncbi Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 43:176-83. 2013
  2. ncbi Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi chou, Suntou gun, Shizuoka, Japan
    Lung Cancer 74:457-61. 2011
  3. ncbi Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Suntou gun, Shizuoka 411 8777, Japan
    Anticancer Res 29:2747-51. 2009
  4. ncbi Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeons
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi cho, Suntou gun, Shizuoka, 411 8777, Japan
    Med Oncol 27:932-7. 2010
  5. ncbi Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study
    Takehito Shukuya
    Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007, Nagaizumi, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 40:1135-8. 2010
  6. ncbi Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease
    T Shukuya
    Department of Respiratory Medicine, Juntendo University, School of Medicine, Bunkyou ku, Tokyo, Japan
    Anticancer Res 30:4357-61. 2010
  7. ncbi Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
    Cancer Sci 102:1032-7. 2011
  8. ncbi Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer
    Minehiko Inomata
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Anticancer Res 31:4519-23. 2011
  9. ncbi Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka, 411 8777, Japan
    Anticancer Res 32:675-80. 2012

Collaborators

Detail Information

Publications9

  1. ncbi Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 43:176-83. 2013
    ....
  2. ncbi Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi chou, Suntou gun, Shizuoka, Japan
    Lung Cancer 74:457-61. 2011
    ....
  3. ncbi Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Suntou gun, Shizuoka 411 8777, Japan
    Anticancer Res 29:2747-51. 2009
    ..New therapeutic modalities are needed for non-small cell lung cancer (NSCLC) patients whose tumors have become resistant to gefitinib...
  4. ncbi Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeons
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi cho, Suntou gun, Shizuoka, 411 8777, Japan
    Med Oncol 27:932-7. 2010
    ....
  5. ncbi Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study
    Takehito Shukuya
    Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007, Nagaizumi, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 40:1135-8. 2010
    ..The safety and efficacy of weekly paclitaxel therapy was evaluated for pancreatic cancer patients with malignant ascites in this retrospective study...
  6. ncbi Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease
    T Shukuya
    Department of Respiratory Medicine, Juntendo University, School of Medicine, Bunkyou ku, Tokyo, Japan
    Anticancer Res 30:4357-61. 2010
    ..Since advanced non-small cell lung cancer (NSCLC) patients with the interstitial lung disease (ILD) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients...
  7. ncbi Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
    Cancer Sci 102:1032-7. 2011
    ..000028; DCR: 67-70%vs 92-93%, P = 0.000014; mPFS: 3.0 vs 9.4 months, P = 0.0001, respectively). Gefitinib is less effective in non-adenocarcinoma NSCLC harboring EGFR mutations than adenocarcinoma harboring EGFR mutations...
  8. ncbi Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer
    Minehiko Inomata
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Anticancer Res 31:4519-23. 2011
    ..We retrospectively evaluated the clinical course of patients who received continuous administration of EGFR-TKIs after disease progression was detected solely in bone lesions...
  9. ncbi Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka, 411 8777, Japan
    Anticancer Res 32:675-80. 2012
    ..However, there have been no studies that have compared S-1 and CDDP combined with thoracic radiotherapy (TRT) with VNR and CDDP combined with TRT...